AngioDynamics Stock Earnings Estimates Cut by Zacks Research

Key Points

• Zacks Research lowered AngioDynamics’ Q2 FY2027 EPS estimate to a loss of $0.10 from a loss of $0.08 and maintains a “Hold” rating. Its FY2027 forecast now calls for a $0.26-per-share loss, signaling expectations for continued unprofitability.
• AngioDynamics recently exceeded quarterly expectations, reporting a $0.04 adjusted loss per share versus the expected $0.11 loss, while revenue of $80.92 million slightly surpassed estimates.
• Analyst sentiment is mixed: the stock has a “Moderate Buy” consensus rating and an average $19 price target versus a recent price of $11.99, while CFO Stephen Trowbridge sold approximately $289,756 in shares.

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Stock analysts at Zacks Research reduced their Q2 2027 earnings per share (EPS) estimates for shares of AngioDynamics in a report issued on Thursday, October 29th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn ($0.10) per share for the quarter, down from their prior forecast of ($0.08). Zacks Research has a "Hold" rating on the stock. The consensus estimate for AngioDynamics' current full-year earnings is ($0.27) per share. Zacks Research also issued estimates for AngioDynamics' Q3 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.26) EPS, Q1 2028 earnings at ($0.08) EPS, Q2 2028 earnings at ($0.03) EPS, Q3 2028 earnings at ($0.02) EPS, Q4 2028 earnings at ($0.03) EPS, FY2028 earnings at ($0.16) EPS and Q1 2029 earnings at ($0.05) EPS.

A number of other equities analysts also recently commented on ANGO. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 price objective on shares of AngioDynamics in a research note on Friday, October 9th. Wall Street Zen cut AngioDynamics from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. HC Wainwright dropped their price target on shares of AngioDynamics from $19.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, October 13th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AngioDynamics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $19.00.

AngioDynamics Price Performance

AngioDynamics stock opened at $11.99 on Monday. AngioDynamics has a twelve month low of $9.39 and a twelve month high of $16.29. The stock has a market capitalization of $504.18 million, a PE ratio of -15.37 and a beta of 0.30. The company has a 50 day moving average of $14.18 and a 200-day moving average of $12.47.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. The company had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS.

Insider Buying and Selling at AngioDynamics

In other news, CFO Stephen Trowbridge sold 23,615 shares of the company's stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $12.27, for a total transaction of $289,756.05. Following the completion of the transaction, the chief financial officer directly owned 280,461 shares of the company's stock, valued at $3,441,256.47. This represents a 7.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.00% of the company's stock.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of AngioDynamics in the 2nd quarter worth approximately $49,480,000. Weber Capital Management LLC ADV purchased a new position in shares of AngioDynamics during the 2nd quarter worth approximately $17,649,392. Bastion Asset Management Inc. grew its holdings in AngioDynamics by 17.4% during the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier's stock valued at $14,107,000 after purchasing an additional 194,822 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of AngioDynamics by 3.5% during the first quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier's stock worth $10,786,000 after purchasing an additional 32,476 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY purchased a new stake in shares of AngioDynamics in the second quarter valued at about $8,732,000. Hedge funds and other institutional investors own 89.43% of the company's stock.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Zacks Research raised its FY2028 EPS forecast to a loss of $0.16 per share from a loss of $0.17 and improved its Q2 2028 estimate to a loss of $0.03 from $0.07. It also raised its Q4 2028 forecast to a loss of $0.03 from $0.04, suggesting some improvement in longer-term expectations. Zacks Research analyst ratings
• Positive Sentiment: AngioDynamics previously exceeded quarterly expectations, reporting a $0.04 adjusted loss per share versus the consensus estimate of a $0.11 loss, while revenue of $80.92 million was slightly above forecasts. Analysts’ average price target remains well above the current trading level, supporting potential upside if execution improves.
• Neutral Sentiment: Institutional ownership remains high at approximately 89%, and several funds recently initiated or increased positions. However, these changes were relatively small and may have limited immediate influence on the stock.
• Negative Sentiment: Zacks Research lowered its FY2027 EPS forecast to a loss of $0.26 from $0.24, cut Q2 2027 to a loss of $0.10 from $0.08, and reduced Q3 2027 to a loss of $0.10 from $0.05. It also lowered Q1 2028 and Q3 2028 estimates, indicating expectations for prolonged losses and weaker near-term profitability. Zacks Research analyst ratings
• Negative Sentiment: CFO Stephen Trowbridge sold 1,720 shares for approximately $20,932. Although the sale reduced his stake by only 0.56% and he still owns more than 304,000 shares, insider selling can add modest pressure to investor sentiment. AngioDynamics CFO stock sale

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company's portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.